Switch theme
Sign up to access all valuation multiples
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
2014
57
LTM Revenue $2.2M
LTM EBITDA n/a
$7.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Eyenovia has a last 12-month revenue of $2.2M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Eyenovia achieved revenue of $4K and an EBITDA of -$24.1M.
Eyenovia expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Eyenovia valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $4K | XXX | XXX | XXX |
| Gross Profit | $12.4M | n/a | XXX | XXX | XXX |
| Gross Margin | Infinity% | 0% | XXX | XXX | XXX |
| EBITDA | -$26.3M | -$24.1M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -636547% | XXX | XXX | XXX |
| Net Profit | -$12.8M | -$28.0M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -739666% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Eyenovia's stock price is $1.
Eyenovia has current market cap of $2.1M, and EV of $7.9M.
See Eyenovia trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.9M | $2.1M | XXX | XXX | XXX | XXX | $-5.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Eyenovia has market cap of $2.1M and EV of $7.9M.
Eyenovia's trades at 3.6x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Eyenovia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Eyenovia and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $7.9M | XXX | XXX | XXX |
| EV/Revenue | 2096.2x | XXX | XXX | XXX |
| EV/EBITDA | -0.3x | XXX | XXX | XXX |
| P/E | -0.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEyenovia's NTM/LTM revenue growth is 167%
Eyenovia's revenue per employee for the last fiscal year averaged $0K, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Eyenovia's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Eyenovia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Eyenovia and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | Infinity% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -636547% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -8% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -636380% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 28978% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 299266% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 342641% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 670886% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Eyenovia acquired XXX companies to date.
Last acquisition by Eyenovia was XXXXXXXX, XXXXX XXXXX XXXXXX . Eyenovia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Eyenovia founded? | Eyenovia was founded in 2014. |
| Where is Eyenovia headquartered? | Eyenovia is headquartered in United States of America. |
| How many employees does Eyenovia have? | As of today, Eyenovia has 57 employees. |
| Who is the CEO of Eyenovia? | Eyenovia's CEO is Mr. Michael M. Rowe. |
| Is Eyenovia publicy listed? | Yes, Eyenovia is a public company listed on NAS. |
| What is the stock symbol of Eyenovia? | Eyenovia trades under EYEN ticker. |
| When did Eyenovia go public? | Eyenovia went public in 2018. |
| Who are competitors of Eyenovia? | Similar companies to Eyenovia include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Eyenovia? | Eyenovia's current market cap is $2.1M |
| What is the current revenue of Eyenovia? | Eyenovia's last 12-month revenue is $2.2M. |
| What is the current EV/Revenue multiple of Eyenovia? | Current revenue multiple of Eyenovia is 3.6x. |
| Is Eyenovia profitable? | Yes, Eyenovia is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
